Video

Dr. Erhunmwunsee on Factors of Disparity in Lung Cancer Treatment

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

Race and socioeconomic status are known drivers of disparity in cancer treatment in general. Patients who come from disadvantaged populations are less likely to receive treatment, and are also potentially less likely to survive due to access to care, Erhunmwunsee explains. Tobacco use is also a driver.

Disparity in care is multifactorial though, and in lung cancer, genomic and genetic difference can also drive disparity, says Erhunmwunsee. For example, EGFR and MET mutations can cause disparity in treatment, as the instances of these mutations can differ between races. These are some of the same disparities in clinical trial participation, adds Erhunmwunsee.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD